UNASSIGNED: We investigated the treatment and outcome of Japanese @entity1 with primary @entity9865 (pPCL) in the @entity7971 of novel agents and analyzed the risk factors affecting survival. Among 3,318 @entity1 with symptomatic @entity1582 ( @entity1582 ), 38 @entity1 were diagnosed with pPCL. The median @entity1349 ( @entity1349 ) of the pPCL @entity1 was 2.85 years, which was significantly extended compared with that in previous reports. The proportion of @entity1 treated with novel agents was 61%. The @entity1349 of the @entity1 treated with novel agents was significantly extended compared with that of @entity1 treated without novel agents according to the generalized Wilcoxon test (2.85 vs. 1.16 years, p = 0.049). This statistical finding suggests that treatment with novel agents could have prevented @entity204 in the @entity1 with pPCL. Age was the only statistically significant prognostic factor associated with an inferior @entity1349 (hazard ratio 4.57). Five @entity1 received maintenance therapy with novel agents, and their @entity1349 tended to be longer than that of the other @entity1 without maintenance (4.45 vs. 2.85 years). Unlike @entity1582 , @entity1349 for pPCL has not been improved significantly over the last decade, especially in elderly @entity1 . Therefore, it is important to establish the treatment strategy, particularly after induction treatment.

Primary XXXX in the @entity7971 of Novel Agents: A Multicenter Study of the Japanese Society of @entity1582 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7971 :: ('26284', 'Gene') :: ['era'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity9865 :: ('MESH:D007952', 'Disease') :: ['plasma cell leukemia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['early death'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity9865 :: (MESH:D007952,Disease) :: ['Plasma Cell Leukemia']
